Liquidia Technologies
Morrisville
About Liquidia Technologies
Liquidia Technologies is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using our proprietary PRINT technology to transform the lives of patients. PRINT technology is a particle engineering platform that enables the precise production of uniform drug particles designed to improve the safety, efficacy, and performance of a wide range of therapies. Currently, Liquidia is developing two product candidates from its own pipeline: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. In addition to developing our own product candidates, Liquidia collaborates with leading pharmaceutical companies to apply our PRINT technology across a wide range of therapeutic areas, molecule types, and routes of administration.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $533.4M
- Funding stage: IPO
- Last round: Post-IPO Debt (Jun 2025)
- Ticker: nasdaq:LQDA
- Website: liquidia.com
- Phone: (919)328-4400
Industries & Categories
Biopharma, Biotechnology, Health Care, Nanotechnology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/liquidia-technologies-18406 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.